Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|August 6, 2026
ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine the most consequential risks facing early-stage biotech development, why recruitment spending targets the wrong funnel level, and industry deal speculation clarifications.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part two of her interview , Stella K. Vnook, CEO of Kaida BioPharma and founder of Aviva Ventures, identified the funding gap and indication selection trade-offs as the most consequential risks facing early-stage programs today. Great assets still fall behind when those early decisions go wrong, and the consequences cascade through all subsequent development planning. - In a
new contributed article , Yuchen Gan examined where the recruitment funnel leaks worst, finding that the biggest loss occurs at the top when patients and trials never meet rather than at the bottom when reached patients decline to participate. Over 56 percent of enrollment shortfall stems from lack of suitable trial availability at where patients receive care, yet most recruitment budgets focus on persuasion optimization and AI-powered screening of already-visible candidates. - A
senior source denied any active discussions between AstraZeneca and Bristol Myers Squibb over a potential 400-billion-dollar combination, stating flatly there was no deal and never was a basis for one. The denial followed three days of market speculation triggered by initial reports, with regulatory risk from US antitrust authorities cited as a likely impediment had talks proceeded.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
3
Using AI to Design Better Trials Before the First Patient Enrolls: Q&A with Claire Riches, Citeline
4
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
5